Analysts think AVTX stock price could increase by 529%
Apr 07, 2025, 11:25 AM
-15.85%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
9 analysts think AVTX stock price will increase by 528.52%. The current median analyst target is $35.70 compared to a current stock price of $5.68. The lowest analysts target is $18.18 and the highest analyst target is $50.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
